We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


PBI Announces Collaborative Agreement with Clinigene International

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PBI Announces Collaborative Agreement with Clinigene International"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pacific Biomarkers (PBI) and Clinigene International Limited have announced a collaborative agreement for addressing specialty biomarker and high-end clinical trial laboratory needs of the global pharmaceutical and biotechnology industry.

"PBI is a recognized global leader in providing specialty biomarkers and clinical diagnostic assay services to discovery- and development-based life science enterprises. We are delighted that PBI has selected Clinigene as its partner in India. We are excited and look forward to supporting PBI in extending and expanding its specialist service offerings," stated Peter Bains, Chief Operating Officer of Clinigene, a subsidiary of Biocon, India's leading biotechnology company.

"This partnership with Clinigene provides us access to India, an emerging hub for drug development and contract research. Further, Clinigene's state-of-the-art facilities and highly qualified staff help us offer to all of our clients an economic option for conducting their biomarker and specialty clinical lab tests. We are also excited about Clinigene's unique capabilities in cell-based assays and immunoanalytical testing services, which are of great interest to the global pharmaceutical and biotechnology community," said Ronald Helm, CEO of Pacific Biomarkers.